Allspring Global Investments Holdings LLC Has $24.10 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Allspring Global Investments Holdings LLC trimmed its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 10.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,410 shares of the biotechnology company's stock after selling 17,842 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.28% of Ascendis Pharma A/S worth $24,100,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ASND. Price T Rowe Associates Inc. MD grew its holdings in Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock worth $269,374,000 after buying an additional 336,976 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company's stock valued at $37,849,000 after purchasing an additional 234,446 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock valued at $572,341,000 after purchasing an additional 229,995 shares in the last quarter. Fred Alger Management LLC boosted its stake in Ascendis Pharma A/S by 65.0% during the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company's stock valued at $41,879,000 after purchasing an additional 120,952 shares in the last quarter. Finally, Tri Locum Partners LP boosted its stake in Ascendis Pharma A/S by 102.1% during the 2nd quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company's stock valued at $31,062,000 after purchasing an additional 115,092 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages have issued reports on ASND. Evercore ISI increased their price target on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an "outperform" rating in a research note on Tuesday, September 17th. Oppenheimer reaffirmed an "outperform" rating and set a $190.00 price target (up from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th. TD Cowen increased their price target on Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a "buy" rating in a research note on Monday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, September 16th. Finally, Jefferies Financial Group raised their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a "buy" rating in a research note on Tuesday, August 13th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $195.92.

Ascendis Pharma A/S Stock Up 1.7 %

Shares of ASND traded up $2.12 during mid-day trading on Thursday, reaching $129.81. The company's stock had a trading volume of 205,811 shares, compared to its average volume of 448,527. The business has a fifty day moving average of $134.90 and a 200 day moving average of $134.65. The company has a market cap of $7.56 billion, a price-to-earnings ratio of -13.51 and a beta of 0.64. Ascendis Pharma A/S has a 1 year low of $85.38 and a 1 year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. On average, analysts predict that Ascendis Pharma A/S will post -7.2 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.